# Partisan Management Group

> Partisan Management Group is a VC fund backing Medical and Health Care. See 25 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Evergreen, United States
- Total investments: 25
- Last investment: Oct 2018
- Lead investor: 12%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/partisan-management-group-inc
- Website: http://www.partisanmgmt.com

Partisan Management Group is a highly successful, early stage venture capital investor in medical device companies.

## Contacts

5 contacts available for Partisan Management Group. Shizune tracks 2 team members at Partisan Management Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/partisan-management-group?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $6.1M–$30M |
| Series B | $16M–$50M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 8 | 32% |
| Health Care | 8 | 32% |
| Biotechnology | 7 | 28% |
| Medical Device | 5 | 20% |
| Pharmaceutical | 3 | 12% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 6 | 24% |
| Series A | 3 | 12% |
| Series B | 3 | 12% |
| Series D | 3 | 12% |
| Seed | 2 | 8% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 10 | 40% |
| Ireland | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Karen Cassidy | Managing Director | 0 | https://shizune.co/investors/profile/karen-cassidy |
| Norman Weldon | Managing Director | 0 | https://shizune.co/investors/profile/norman-weldon |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Enable Injections | Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. | $50M | Series B | Oct 25, 2018 |  |
| TriSalus Life Sciences | Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue. | $12.8M | Series D | Mar 03, 2017 |  |
| Ponce De Leon Pharmaceuticals | Ponce De Leon Pharmaceuticals is a privately financed development stage company, committed to the extension of human health span, endeavoring to offer more healthy years of living. In conjunction with the Buck Institute for Research on Aging, the Company has developed a formulation comprised of GRAS (Generally Regarded As Safe) components. Thisformulation has been shown to radically increase mean lifespan in the invertebrate model (C. Elegan), well beyond any previously published data on drugs or compounds. Testing has now begun at the Buck Institute in the mammalian model (mouse), and the Company hopes to have a patent pending product available to the public at the conclusion of those studies, or in about three years. |  | Seed | Jan 03, 2017 |  |
| Enable Injections | Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. | $30M | Series A | Oct 05, 2016 |  |
| TriSalus Life Sciences | Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue. | $15M | Series C | Dec 02, 2015 |  |
| Enable Injections | Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. |  |  | Oct 20, 2015 |  |
| Preceptis Medical | Preceptis Medical is a medical device manufacturer developing surgical tools that allow ear tube procedures to be performed with reduced pain and surgical time for the pediatric patient. Its pediatric surgical technology Hummingbird TTS offers an alternative to general anesthesia and minimizes surgical trauma during ear tube placement, enablingphysicians to use moderate sedation for routine ear tube procedures.Preceptis Medical was founded in 2011 and is headquartered in Maple Grove, Minnesota. | $976K | Convertible Note | Jun 10, 2015 |  |
| Neuronetics | Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. | $34.3M | Series F | Apr 27, 2015 |  |
| Ponce De Leon Pharmaceuticals | Ponce De Leon Pharmaceuticals is a privately financed development stage company, committed to the extension of human health span, endeavoring to offer more healthy years of living. In conjunction with the Buck Institute for Research on Aging, the Company has developed a formulation comprised of GRAS (Generally Regarded As Safe) components. Thisformulation has been shown to radically increase mean lifespan in the invertebrate model (C. Elegan), well beyond any previously published data on drugs or compounds. Testing has now begun at the Buck Institute in the mammalian model (mouse), and the Company hopes to have a patent pending product available to the public at the conclusion of those studies, or in about three years. |  | Seed | Jun 25, 2014 |  |
| Preceptis Medical | Preceptis Medical is a medical device manufacturer developing surgical tools that allow ear tube procedures to be performed with reduced pain and surgical time for the pediatric patient. Its pediatric surgical technology Hummingbird TTS offers an alternative to general anesthesia and minimizes surgical trauma during ear tube placement, enablingphysicians to use moderate sedation for routine ear tube procedures.Preceptis Medical was founded in 2011 and is headquartered in Maple Grove, Minnesota. | $4.4M |  | Jan 31, 2014 |  |

10 of 25 investments shown.

## Co-investors
- [Camden Partners](https://shizune.co/investors/profile/camden-partners) — VC Fund, 4 deals together
- [High Country Venture](https://shizune.co/investors/profile/high-country-venture) — VC Fund, 3 deals together
- [ORI Capital](https://shizune.co/investors/profile/ori-capital) — VC Fund, 3 deals together
- [Charter Venture Group](https://shizune.co/investors/profile/charter-venture-group) — VC Fund, 2 deals together
- [CincyTech](https://shizune.co/investors/profile/cincytech) — VC Fund, 2 deals together
- [Cintrifuse](https://shizune.co/investors/profile/cintrifuse) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Ireland](https://shizune.co/investors/medical-vc-funds-ireland)
- [Medical Device Investors in Ireland](https://shizune.co/investors/medical-device-investors-ireland)
- [Medical Device VC Funds in Ireland](https://shizune.co/investors/medical-device-vc-funds-ireland)
- [Health Care Investors in Ireland](https://shizune.co/investors/health-care-investors-ireland)
- [Health Care VC Funds in Ireland](https://shizune.co/investors/health-care-vc-funds-ireland)

## FAQ

### What does Partisan Management Group invest in?

Partisan Management Group invests primarily in Medical, Health Care and Biotechnology startups, most often at Funding Round and Series A stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Partisan Management Group's check size?

Partisan Management Group typically joins rounds of $6.1M–$30M at Series A and $16M–$50M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Partisan Management Group participates in.

### How do I contact Partisan Management Group?

Public channels for Partisan Management Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Partisan Management Group?

The team at Partisan Management Group includes Karen Cassidy (Managing Director) and Norman Weldon (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co